United Kingdom

People: Novavax Inc (NVAX.OQ)

NVAX.OQ on NASDAQ Stock Exchange Global Select Market

19 Jul 2019
Change (% chg)

$-0.03 (-0.65%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Glenn, Gregory 

Dr. Gregory M. Glenn M.D., is President, Research and Development of Novavax, Inc. Previously served as Senior Vice President, Research and Development since January 2014, as Senior Vice President, Chief Medical Officer from January 2011 to January 2014, and Senior Vice President and Chief Scientific Officer from June 2010 to January 2011. Prior to joining the Company, Dr. Glenn was the Chief Scientific Officer and founder of Iomai Corporation, which was acquired in 2008 by Intercell AG, an associate in international health at Johns Hopkins University’s School of Public Health and a clinical and basic research scientist at Walter Reed Army Institute of Research. Dr. Glenn received a B.A. in biology and chemistry from Whitman College and a M.D. from Oral Roberts University School of Medicine. He also completed the Medical Research Fellowship at the Walter Reed Army Institute of Research.

Basic Compensation

Total Annual Compensation, USD 679,500
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 541,750
Fiscal Year Total, USD 1,221,250

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

James Young


Stanley Erck


John Trizzino


Gregory Glenn


John Herrmann


Jody Lichaa

As Of  31 Dec 2017